What the public record says
The TGA says amendments to the Therapeutic Goods Regulations 1990 mean compounded GLP-1 RA products are no longer able to be compounded by pharmacists and supplied to patients. The change applies to GLP-1 RA analogues compounded on or after 1 October 2024.
What buyers should check
- The TGA announced the change on 18 June 2024.
- The amendments apply to all medicines containing GLP-1 RA analogues, regardless of dosage form, compounded on or after 1 October 2024.
- Your Solution Compounding Pharmacy later gave a court-enforceable undertaking about advertising prescription-only compounded weight-loss medicines.
- Peptide Checker treats GLP-1 clinic pages as a separate lane from grey-market research peptide stores.
- A clinic-model score needs prescription path, clinician path, pharmacy path, advertising compliance, and current supply evidence.
Source links
Use this regulatory brief to ask better supplier questions. Do not convert a market-level warning into a vendor-specific claim unless the vendor page has a source attached.
Open vendor scorecards